Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm

Wed Feb 8 10:54:43 2023

(2022) Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm. Iranian journal of immunology : IJI. pp. 321-329. ISSN 1735-367X (Electronic) 1735-1383 (Linking)

Full text not available from this repository.

Official URL: https://www.ncbi.nlm.nih.gov/pubmed/36190385

Abstract

BACKGROUND: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2). OBJECTIVES: To compare the antibody response of healthy individuals vaccinated with either the AstraZeneca (ChAdOx1 nCoV-19) or the Sinopharm (BBIBP-CorV) vaccine, in those who had no prior infection with SARS-CoV-2. METHODS: Thirty seven participants were included, of which 17 were administered the AstraZeneca (ChAdOx1 nCoV-19) vaccine, while 20 were given the Sinopharm (BBIBP-CorV) vaccine. SARS-CoV-2 neutralizing antibody and anti-receptor-binding domain (RBD) IgG levels were checked 4 weeks after giving the first and the second dose of either vaccine using the enzyme-linked immunosorbent assay (ELISA) technique. RESULTS: The AstraZeneca (ChAdOx1 nCoV-19) vaccine exhibited a higher levels of anti-(RBD) IgG compared with the Sinopharm (BBIBP-CorV) in both the first (14.51 mug/ml vs. 1.160 mug/ml) and the second (46.68 mug/ml vs. 11.43 mug/ml) doses. About neutralizing Abs, the titer of the antibody was higher in the AstraZeneca (ChAdOx1 nCoV-19) recipients than in the Sinopharm (BBIBP-CorV) subjects after the first (7.77 mug/ml vs. 1.79 mug/ml, p < 0.0001) and the second dose (10. 36 mug/ml vs. 4.88 mug/ml, p < 0.0001). CONCLUSIONS: Recipients vaccinated with two doses of the AstraZeneca (ChAdOx1 nCoV-19) had superior quantitative antibody levels than Sinopharm (BBIBP-CorV)-vaccinated subjects. These data suggest that a booster dose may be needed for the Sinopharm (BBIBP-CorV) recipients, to control the COVID-19 pandemic.

Item Type: Article
Creators:
CreatorsEmail
Anvari, E.UNSPECIFIED
Ghamar Talepoor, A.UNSPECIFIED
Eshkevar Vakili, M.UNSPECIFIED
Karimi, N.UNSPECIFIED
Ataollahi, M.UNSPECIFIED
Najafi, G.UNSPECIFIED
Kabalitz, D.UNSPECIFIED
Ahmadi, I.UNSPECIFIED
Kalantar, K.UNSPECIFIED
Keywords: Antibodies, Neutralizing Antibodies, Viral Antibody Formation *COVID-19/prevention & control ChAdOx1 nCoV-19 Humans Immunoglobulin G Pandemics/prevention & control SARS-CoV-2 Vaccination *Viral Vaccines
Divisions:
Page Range: pp. 321-329
Journal or Publication Title: Iranian journal of immunology : IJI
Journal Index: Pubmed
Volume: 19
Number: 3
Identification Number: https://doi.org/10.22034/iji.2022.94298.2300
ISSN: 1735-367X (Electronic) 1735-1383 (Linking)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4059

Actions (login required)

View Item View Item